Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
300 participants
OBSERVATIONAL
2019-11-12
2020-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Several Rapid Diagnostic tests (RDTs) are currently in the market but only limited data on their performance are available, rendering them unsuitable to replace laboratory conventional tests. In addition, RDTs have been developed for single disease diagnosis and remain costly for Low and Middle Income Countries (LMIC).
Chembio, in collaboration with FIND (Foundation for Innovative New Diagnostics) and MORU (Mahidol Oxford Tropical Medicine Research Unit), has developed a multiplex lateral flow immunoassay (DPP® Fever Panel II Assay) that is able to detect serum immunoglobulin M (IgM) and specific microbial antigen of the most common agents of Acute Febrile Illness (AFI) in Asia. The assay comes with a reader that provides results interpretation to the operator.
So far, DPP II assay performance has been estimated using a limited number of retrospective serum samples. More data are required to assess the performance of the assay using prospective serum samples. In addition, only limited data are available regarding the performance of the assay using blood samples. FIND will conduct a clinical trial to estimate the clinical performance of the assay in comparison to reference tests, using blood and serum samples and in intended settings of use.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Innovative Public-private Partnership to Target Subsidized Antimalarials in the Retail Sector
NCT02199977
Algorithm Using a Rapid Diagnostic Test for the Management of Childhood Febrile Diseases.
NCT05285657
Training in Fever Case Management With Rapid Diagnostic Tests (RDTs) for Malaria in Uganda
NCT00716599
Impact of Differential and Systematic Diagnosis of Dengue, Chikungunya and Malaria on Patient Management and Antibiotic Use in West Africa
NCT06257810
A Cohort Study to Determine the Incidence of Dengue Fever and to Build Capacity for Dengue Vaccine Trials in Dengue-endemic Regions of South Asia
NCT02570152
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AFI patients
Blood will be collected from patients presenting with an undifferentiated fever.
Samples will be tested with:
* the Malaria Ag Pf/Pan test SD Bioline
* the SD Bioline Dengue Duo IgM/IgG/NS1
* the DPP Zika Chikungunya Dengue test from Chembio
* the DPP Fever Panel II assay
* the Leptospira IgM ELISA test from Serion
* an in-house ELISA tests for scrub and murine typhus IgM
* blood culture for detection of Burkholderia pseudomallei
DPP Fever Panel II assay and DPP Micro Readers
Detection of common causes of acute febrile illnesses in Asia
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DPP Fever Panel II assay and DPP Micro Readers
Detection of common causes of acute febrile illnesses in Asia
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Fever (≥ 37.5 °C)
* Illness duration \< 14 days
* Willingness to provide blood samples by venepuncture
Exclusion Criteria
* Non-infectious known or suspected cause of fever
* No left over blood sample or insufficient volume of left over sample
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Foundation for Innovative New Diagnostics, Switzerland
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
LOMWRU, Mahosot Hospital
Vientiane, , Laos
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FE004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.